2024
Procedure Volume and Outcomes With WATCHMAN Left Atrial Appendage Occlusion
Friedman D, Du C, Zimmerman S, Tan Z, Lin Z, Vemulapalli S, Kosinski A, Piccini J, Pereira L, Minges K, Faridi K, Masoudi F, Curtis J, Freeman J. Procedure Volume and Outcomes With WATCHMAN Left Atrial Appendage Occlusion. Circulation Cardiovascular Interventions 2024, 17: e013466. PMID: 38889251, PMCID: PMC11189610, DOI: 10.1161/circinterventions.123.013466.Peer-Reviewed Original ResearchConceptsVolume-outcome relationshipLikelihood of procedural successLeft atrial appendage occlusionProcedural successProcedure volumeAppendage occlusionNational Cardiovascular Data Registry LAAO RegistryVolume quartilesLeft atrial appendage occlusion devicesThree-level hierarchical generalized linear modelsMinimum volume thresholdsWatchman FLX deviceProcedural success rateHierarchical generalized linear modelsAssociated with outcomePhysician volumeWATCHMAN procedureFLX deviceOcclusion deviceVolume thresholdCardiovascular proceduresPhysiciansHospitalNational analysisSuccess rate
2023
Association Between Claims‐Defined Frailty and Outcomes Following 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND‐DAPT Study
Faridi K, Strom J, Kundi H, Butala N, Curtis J, Gao Q, Song Y, Zheng L, Tamez H, Shen C, Secemsky E, Yeh R. Association Between Claims‐Defined Frailty and Outcomes Following 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND‐DAPT Study. Journal Of The American Heart Association 2023, 12: e029588. PMID: 37449567, PMCID: PMC10382113, DOI: 10.1161/jaha.123.029588.Peer-Reviewed Original ResearchConceptsExtended duration dual antiplatelet therapyDuration dual antiplatelet therapyNet adverse clinical eventsDual antiplatelet therapyAdverse clinical eventsPercutaneous coronary interventionCoronary interventionClinical eventsNonfrail patientsAntiplatelet therapyFrail patientsClaims dataMonths of DAPTClaims-based indexYears of ageMajor bleedingCause mortalityMultivariable adjustmentOlder patientsDAPT studyResults PatientsBackground FrailtyMyocardial infarctionClinical trialsMedicare claimsImpact of Preprocedure Imaging for Left Atrial Appendage Occlusion Insights From the NCDR LAAO Registry
Clarke J, Higgins A, Wang Y, Faridi K, Curtis J, Freeman J, Friedman D. Impact of Preprocedure Imaging for Left Atrial Appendage Occlusion Insights From the NCDR LAAO Registry. JACC Cardiovascular Interventions 2023, 16: 1317-1328. PMID: 37316143, DOI: 10.1016/j.jcin.2023.05.008.Peer-Reviewed Original ResearchMeSH KeywordsAtrial AppendageHumansHypertensionRegistriesTomography, X-Ray ComputedTreatment OutcomeConceptsDevice successImplantation successPreprocedure imagingProcedure successLAAO proceduresAbnormal renal functionAtrial appendage occlusionMultivariable logistic regressionOutcomes of interestMagnitude of benefitLAAO implantationPrior thromboembolismUncontrolled hypertensionRate of useRenal functionAppendage occlusionProcedural successUniversity HospitalLogistic regressionCMR useOverall rateCMRPatientsPreprocedureRegistryWatchman device migration and embolization: A report from the NCDR LAAO Registry
Friedman D, Freeman J, Zimmerman S, Tan Z, Pereira L, Faridi K, Curtis J. Watchman device migration and embolization: A report from the NCDR LAAO Registry. Journal Of Cardiovascular Electrophysiology 2023, 34: 1192-1195. PMID: 37078339, PMCID: PMC10290479, DOI: 10.1111/jce.15909.Peer-Reviewed Original ResearchConceptsWATCHMAN procedureSurgical retrievalDevice migrationMortality rateAtrial appendage closure deviceHospital mortality rateAnnual procedure volumeCardiac surgeryHospital eventsPostdischarge eventsOstial sizeDevice embolizationTaller patientsRetrospective analysisClosure deviceLAA ostiumPatientsProcedure volumeHigh mortalitySurgerySubstantial proportionEmbolizationRegistryGreater body massBody massTrends in Spending and Claims for P2Y12 Inhibitors by Medicare and Medicaid From 2015 to 2020
Essa M, Ross J, Dhruva S, Desai N, Yeh R, Faridi K. Trends in Spending and Claims for P2Y12 Inhibitors by Medicare and Medicaid From 2015 to 2020. Journal Of The American Heart Association 2023, 12: e028869. PMID: 37042289, PMCID: PMC10227267, DOI: 10.1161/jaha.122.028869.Peer-Reviewed Original Research
2022
Days at home after transcatheter or surgical aortic valve replacement in high-risk patients
Chung M, Butala N, Faridi K, Almarzooq Z, Liu D, Xu J, Song Y, Baron S, Shen C, Kazi D, Yeh R. Days at home after transcatheter or surgical aortic valve replacement in high-risk patients. American Heart Journal 2022, 255: 125-136. PMID: 36309128, DOI: 10.1016/j.ahj.2022.10.080.Peer-Reviewed Original ResearchConceptsSurgical aortic valve replacementTranscatheter aortic valve replacementHigh-risk patientsAortic valve replacementHigh-risk trialsValve replacementIndex hospitalizationRisk trialsLong-term acute care hospitalSelf-expanding bioprosthesisAcute care hospitalsSkilled nursing facilitiesPatient-centered perspectiveFirst yearIndex LOSTAVR patientsCare hospitalEmergency departmentObservation staysPostprocedural courseLandmark analysisMedicare feeNursing facilitiesService claimsPatientsDays at Home After Transcatheter vs Surgical Aortic Valve Replacement in Intermediate-Risk Patients
Chung M, Faridi KF, Kazi DS, Almarzooq ZI, Song Y, Baron SJ, Yeh RW. Days at Home After Transcatheter vs Surgical Aortic Valve Replacement in Intermediate-Risk Patients. JAMA Cardiology 2022, 7: 110-112. PMID: 34668923, PMCID: PMC8529525, DOI: 10.1001/jamacardio.2021.4036.Peer-Reviewed Original Research
2021
Applicability of Transcatheter Aortic Valve Replacement Trials to Real-World Clinical Practice Findings From EXTEND-CoreValve
Butala NM, Secemsky E, Kazi DS, Song Y, Strom JB, Faridi KF, Brennan JM, Elmariah S, Shen C, Yeh RW. Applicability of Transcatheter Aortic Valve Replacement Trials to Real-World Clinical Practice Findings From EXTEND-CoreValve. JACC Cardiovascular Interventions 2021, 14: 2112-2123. PMID: 34620389, PMCID: PMC8855223, DOI: 10.1016/j.jcin.2021.08.006.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacement (TAVR) trialsReal-world patientsReal-world populationTrial patientsPivotal trialsClinical practiceTreatment effectsReplacement trialsAbsolute reductionClinical practice findingsU.S. clinical practiceCharacteristics of patientsCongestive heart failureTrial treatment effectPatient characteristicsTrial cohortHeart failureMedicare cohortAbsolute benefitConventional therapyClinical trialsInverse probability weightingMedicare patientsTAVRMedicare beneficiariesComparing Baseline Data From Registries With Trials Evidence From the CathPCI Registry and DAPT Study
Butala NM, Faridi KF, Secemsky EA, Song Y, Curtis J, Gibson CM, Brindis R, Shen C, Yeh RW. Comparing Baseline Data From Registries With Trials Evidence From the CathPCI Registry and DAPT Study. JACC Cardiovascular Interventions 2021, 14: 1386-1388. PMID: 34167685, PMCID: PMC8800637, DOI: 10.1016/j.jcin.2021.03.065.Peer-Reviewed Original ResearchComparability of Event Adjudication Versus Administrative Billing Claims for Outcome Ascertainment in the DAPT Study
Faridi KF, Tamez H, Butala NM, Song Y, Shen C, Secemsky EA, Mauri L, Curtis JP, Strom JB, Yeh RW. Comparability of Event Adjudication Versus Administrative Billing Claims for Outcome Ascertainment in the DAPT Study. Circulation Cardiovascular Quality And Outcomes 2021, 14: e006589. PMID: 33435731, PMCID: PMC7855905, DOI: 10.1161/circoutcomes.120.006589.Peer-Reviewed Original ResearchConceptsNegative predictive valuePositive predictive valueMyocardial infarctionPredictive valueDAPT studyClinical trialsAdjudicated eventsClaims dataNational Cardiovascular Data Registry CathPCI RegistryClinical events committeeTrial of patientsPercutaneous coronary interventionTrial end pointsKappa statisticsAdjudicated deathCathPCI RegistryCerebrovascular eventsCoronary interventionCumulative incidenceEvents committeeOutcome ascertainmentBilling claimsInpatient hospitalizationBleeding rateCardiovascular disease
2020
Validation of Administrative Claims to Ascertain Outcomes in Pivotal Trials of Transcatheter Aortic Valve Replacement
Butala NM, Strom JB, Faridi KF, Kazi DS, Zhao Y, Brennan JM, Popma JJ, Shen C, Yeh RW. Validation of Administrative Claims to Ascertain Outcomes in Pivotal Trials of Transcatheter Aortic Valve Replacement. JACC Cardiovascular Interventions 2020, 13: 1777-1785. PMID: 32682677, PMCID: PMC7444647, DOI: 10.1016/j.jcin.2020.03.049.Peer-Reviewed Original ResearchMeSH KeywordsAdministrative Claims, HealthcareAgedAged, 80 and overAortic Valve StenosisBioprosthesisClinical Trials as TopicData AccuracyData MiningDatabases, FactualFemaleHealth Services ResearchHeart Valve ProsthesisHumansInternational Classification of DiseasesMaleMedicarePostoperative ComplicationsReproducibility of ResultsTranscatheter Aortic Valve ReplacementTreatment OutcomeUnited StatesConceptsTranscatheter aortic valve replacementAortic valve replacementNegative predictive valuePositive predictive valueValve replacementPivotal trialsAdministrative claimsPredictive valueAortic valve reinterventionProcedural billing codesAcute kidney injuryPermanent pacemaker implantationKappa agreement statisticsBleeding eventsValve reinterventionKidney injuryTrial patientsPacemaker implantationProcedural complicationsOutcome ascertainmentTrial endpointsClinical endpointsMyocardial infarctionInpatient claimsClinical trialsPhysician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment–Elevation Myocardial Infarction in the United States
Faridi KF, Garratt KN, Kennedy KF, Maddox TM, Secemsky EA, Butala NM, Yeh RW. Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment–Elevation Myocardial Infarction in the United States. Circulation Cardiovascular Quality And Outcomes 2020, 13: e006275. PMID: 32156164, DOI: 10.1161/circoutcomes.119.006275.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiologistsCardiology Service, HospitalClopidogrelDrug UtilizationFemaleHemorrhageHumansMaleMiddle AgedPatient DischargePercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPractice Patterns, Physicians'Prasugrel HydrochloridePurinergic P2Y Receptor AntagonistsReceptors, Purinergic P2Y12RegistriesRetrospective StudiesRisk AssessmentRisk FactorsST Elevation Myocardial InfarctionTicagrelorTime FactorsTreatment OutcomeUnited StatesConceptsST-segment elevation myocardial infarctionP2Y12 inhibitor usePotent P2Y12 inhibitorsP2Y12 inhibitorsSTEMI patientsMyocardial infarctionInhibitor useClopidogrel usePrior percutaneous coronary interventionNew P2Y12 inhibitorsSubstantial hospital variationUse of ticagrelorElevation myocardial infarctionPercutaneous coronary interventionRisk of deathStrongest clinical predictorsNational utilization ratesBackground TicagrelorHospital quartilesCoronary interventionPatient characteristicsClinical predictorsTicagrelor useHospital variationRetrospective study
2019
Comparison of Clinical Trials and Administrative Claims to Identify Stroke Among Patients Undergoing Aortic Valve Replacement
Strom JB, Zhao Y, Faridi KF, Tamez H, Butala NM, Valsdottir LR, Curtis J, Brennan JM, Shen C, Boulware M, Popma JJ, Yeh RW. Comparison of Clinical Trials and Administrative Claims to Identify Stroke Among Patients Undergoing Aortic Valve Replacement. Circulation Cardiovascular Interventions 2019, 12: e008231. PMID: 31694411, PMCID: PMC7212938, DOI: 10.1161/circinterventions.119.008231.Peer-Reviewed Original ResearchMeSH KeywordsAdministrative Claims, HealthcareAgedAged, 80 and overAortic ValveAortic Valve StenosisBrain IschemiaClinical Trials as TopicDatabases, FactualFemaleHeart Valve Prosthesis ImplantationHumansIschemic Attack, TransientMaleMedicareRisk AssessmentRisk FactorsStrokeTime FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeUnited StatesConceptsNegative predictive valueAortic valve replacementCerebrovascular eventsInternational ClassificationPositive predictive valuePredictive valueValve replacementNinth RevisionClinical trialsTenth RevisionBilling codesKaplan-Meier estimatesMedicare inpatient claimsSURTAVI trialClinical event adjudicationDevastating complicationIschemic strokeNeurological eventsCerebrovascular diseaseBilling claimsInpatient claimsEvent adjudicationAdministrative claimsHigh riskTrial participantsAd hoc percutaneous coronary intervention in patients with stable coronary artery disease: A report from the National Cardiovascular Data Registry CathPCI Registry
Faridi KF, Rymer JA, Rao SV, Dai D, Wojdyla D, Yeh RW, Wang TY. Ad hoc percutaneous coronary intervention in patients with stable coronary artery disease: A report from the National Cardiovascular Data Registry CathPCI Registry. American Heart Journal 2019, 216: 53-61. PMID: 31401443, DOI: 10.1016/j.ahj.2019.07.004.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryAgedCoronary AngiographyCoronary Artery BypassCoronary Artery DiseaseFemaleHeart FailureHumansLogistic ModelsMaleOdds RatioPercutaneous Coronary InterventionPeripheral Vascular DiseasesPostoperative ComplicationsPostoperative HemorrhageRegistriesRenal Insufficiency, ChronicTreatment OutcomeConceptsStable coronary artery diseaseRisk of AKIPercutaneous coronary interventionAcute kidney injuryCoronary artery diseaseNational Cardiovascular Data Registry CathPCI RegistryCathPCI RegistryCoronary interventionArtery diseaseMultivessel percutaneous coronary interventionCoronary artery bypass graftDiagnostic coronary angiographyArtery bypass graftChronic kidney diseasePeripheral vascular diseaseGlomerular filtration rateChronic total occlusionAKI riskHospital bleedingPCI useKidney injuryCoronary angiographyHeart failureBypass graftUS patients
2018
Chest Pain During Chemotherapy: A Case of Severe Myocardial Bridging.
Mukhopadhyay A, Faridi KF, Asnani A, Osborn EA, Yang JX, Phillips CT, York M. Chest Pain During Chemotherapy: A Case of Severe Myocardial Bridging. Journal Of Invasive Cardiology 2018, 30: e61. PMID: 29958181, PMCID: PMC6247798.Peer-Reviewed Case Reports and Technical Notes
2017
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy
Hess GP, Natarajan P, Faridi KF, Fievitz A, Valsdottir L, Yeh RW. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy. Circulation 2017, 136: 2210-2219. PMID: 29084735, PMCID: PMC5716860, DOI: 10.1161/circulationaha.117.028430.Peer-Reviewed Original ResearchMeSH KeywordsAdministrative Claims, HealthcareAgedAtherosclerosisCost-Benefit AnalysisDrug CostsElectronic Health RecordsEligibility DeterminationFemaleHumansHyperlipoproteinemia Type IIHypolipidemic AgentsInsurance, Health, ReimbursementInsurance, Pharmaceutical ServicesMaleMedicareMiddle AgedPCSK9 InhibitorsProcess Assessment, Health CareProprotein Convertase 9Retrospective StudiesSerine Proteinase InhibitorsTreatment OutcomeUnited StatesConceptsProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitorsAtherosclerotic cardiovascular diseasePCSK9i prescriptionsPayer typeCardiovascular diseaseProprotein convertase subtilisin/kexin type 9 inhibitor therapyHigher low-density lipoprotein cholesterol levelsSubtilisin/kexin type 9 inhibitorsLow-density lipoprotein cholesterol levelsClinical atherosclerotic cardiovascular diseaseDrug's high costNonprimary care providersLipoprotein cholesterol levelsDescriptive cohort studyElectronic medical recordsPCSK9i therapyPrescription approvalThird-party payersStatin useClinical characteristicsStatin intoleranceCohort studyInhibitor therapyPharmacy claimsPrescription claims
2016
Timing of First Postdischarge Follow-up and Medication Adherence After Acute Myocardial Infarction
Faridi KF, Peterson ED, McCoy LA, Thomas L, Enriquez J, Wang TY. Timing of First Postdischarge Follow-up and Medication Adherence After Acute Myocardial Infarction. JAMA Cardiology 2016, 1: 147. PMID: 27437885, DOI: 10.1001/jamacardio.2016.0001.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionMedication adherenceClinic visitsHospital dischargeMyocardial infarctionIntervention Outcomes Network RegistryPlatelet P2Y12 receptor inhibitorsAngiotensin-converting enzyme inhibitorAcute Coronary TreatmentFirst outpatient followImproved care transitionsP2Y12 receptor inhibitorsPostdischarge Follow-upAngiotensin receptor blockersSecondary prevention therapiesLong-term prognosisLow medication adherencePatient medication adherenceProportion of daysLower household incomeGuidelines hospitalsReceptor blockersAcute MIClinical characteristicsCoronary Treatment